What increases the risk of heart disease and how to protect yourself

Cardiovascular disease remains the leading cause of mortality worldwide, claiming over 20.5 million lives annually and representing a staggering 80% preventable condition. Despite remarkable advances in medical technology and treatment protocols, the prevalence of heart disease continues to rise, particularly in developed nations where sedentary lifestyles and dietary patterns contribute significantly to this epidemic. Understanding the multifaceted nature of cardiovascular risk factors becomes crucial for both healthcare professionals and individuals seeking to maintain optimal cardiac health throughout their lives.

Cardiovascular risk factors: understanding modifiable and Non-Modifiable determinants

Cardiovascular risk assessment involves evaluating both modifiable and non-modifiable factors that contribute to coronary heart disease development. Non-modifiable risk factors include age, gender, and genetic predisposition, which serve as foundational elements in risk stratification models. Men over 45 years and women beyond menopause face significantly elevated risks due to hormonal changes and arterial aging processes that occur naturally over time.

Modifiable risk factors present the greatest opportunity for intervention and prevention strategies. These encompass lifestyle choices, environmental exposures, and medical conditions that can be addressed through targeted interventions. The concept of cumulative risk becomes particularly relevant when multiple factors coexist, as their combined effect often exceeds the simple addition of individual risks.

Dyslipidaemia and atherosclerotic plaque formation mechanisms

Dyslipidaemia, characterised by abnormal cholesterol and triglyceride levels, represents one of the most significant modifiable risk factors for cardiovascular disease. Low-density lipoprotein (LDL) cholesterol, often termed “bad cholesterol,” undergoes oxidative modification within arterial walls, triggering inflammatory cascades that promote atherosclerotic plaque formation. This process begins with endothelial dysfunction, where the inner arterial lining becomes permeable to lipoproteins.

High-density lipoprotein (HDL) cholesterol functions as a protective mechanism, facilitating reverse cholesterol transport from peripheral tissues back to the liver for elimination. Optimal HDL levels above 1.2 mmol/L in women and 1.0 mmol/L in men provide cardioprotective benefits, whilst levels below these thresholds increase cardiovascular risk substantially. Triglyceride concentrations above 1.7 mmol/L contribute to atherogenic dyslipidaemia, particularly when combined with low HDL levels.

Hypertension classifications and target organ damage progression

Hypertension affects approximately 28% of adults globally and represents the leading modifiable risk factor for cardiovascular mortality. The current classification system defines normal blood pressure as below 120/80 mmHg, with elevated readings between 120-129 systolic and less than 80 diastolic. Stage 1 hypertension encompasses readings of 130-139/80-89 mmHg, whilst Stage 2 hypertension includes measurements of 140/90 mmHg or higher.

Chronic elevation in blood pressure leads to target organ damage affecting the heart, brain, kidneys, and peripheral vasculature. Left ventricular hypertrophy develops as the heart muscle thickens in response to increased workload, eventually progressing to heart failure if left untreated. Hypertensive retinopathy provides valuable insights into systemic vascular damage, whilst microalbuminuria indicates early kidney involvement in the hypertensive process.

Type 2 diabetes mellitus and accelerated coronary atherosclerosis

Type 2 diabetes mellitus accelerates atherosclerotic processes through multiple pathophysiological mechanisms, including advanced glycation end-product formation, increased oxidative stress, and chronic inflammatory states. Diabetic patients face a two to four-fold increased risk of coronary heart disease compared to non-diabetic individuals, with women losing their pre-menopausal cardioprotective advantage when diabetes develops.

Glycaemic control, measured through HbA1c levels, directly correlates with cardiovascular risk reduction. Target HbA1c levels below 7% (53 mmol/mol) significantly reduce microvascular complications

and macrovascular events such as myocardial infarction and stroke. However, cardiovascular risk in diabetes is not eliminated even with good control, which is why aggressive management of co-existing hypertension, dyslipidaemia, and obesity is equally important. Early screening for prediabetes, lifestyle modification, and the use of cardioprotective agents such as SGLT2 inhibitors and GLP‑1 receptor agonists are increasingly incorporated into modern prevention strategies.

Tobacco use and endothelial dysfunction pathophysiology

Tobacco use remains one of the most potent and entirely preventable risk factors for heart disease. Combustion products in cigarette smoke, including carbon monoxide and free radicals, directly damage the vascular endothelium, the delicate inner lining of arteries that regulates vascular tone and blood flow. This endothelial injury promotes reduced nitric oxide bioavailability, increased vasoconstriction, and a pro-thrombotic state, all of which accelerate atherosclerotic plaque development.

Nicotine itself raises heart rate and blood pressure, increasing myocardial oxygen demand while simultaneously reducing oxygen supply due to carbon monoxide binding to haemoglobin. Over time, these pathophysiological changes lead to increased arterial stiffness, plaque instability, and a markedly higher risk of acute coronary syndromes. Even exposure to second-hand smoke has been shown to impair endothelial function within minutes, underlining why complete avoidance, not just “cutting down,” is essential for cardiovascular protection.

Smoking cessation rapidly reduces cardiovascular risk; within 24 hours, blood pressure and heart rate begin to normalise, and within a year, the risk of coronary heart disease is roughly halved compared to continued smokers. Combining behavioural counselling with pharmacotherapy such as nicotine replacement therapy, varenicline, or bupropion significantly improves quit rates. For individuals with established cardiovascular disease, stopping tobacco is one of the most impactful secondary prevention measures you can take.

Genetic predisposition: familial hypercholesterolaemia and inherited cardiomyopathies

Genetic factors play a substantial role in determining an individual’s baseline risk of heart disease, independent of lifestyle habits. Familial hypercholesterolaemia (FH) is a prime example; this autosomal dominant disorder affects approximately 1 in 250 people and is characterised by extremely high LDL cholesterol levels from birth. Mutations in genes such as LDLR, APOB, or PCSK9 impair LDL clearance, leading to early and aggressive atherosclerosis.

People with untreated heterozygous FH often develop coronary artery disease before the age of 55 in men and 65 in women, while homozygous FH can cause life-threatening cardiovascular events in childhood. Early recognition through family screening and genetic testing allows initiation of high-intensity statins, ezetimibe, and PCSK9 inhibitors, dramatically reducing lifetime risk. You can think of FH as starting the “atherosclerosis clock” decades earlier than usual, which is why proactive treatment is essential.

Inherited cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy, also increase the risk of sudden cardiac death and heart failure. These conditions often follow familial patterns and may present with symptoms such as exertional breathlessness, palpitations, or syncope, but can also remain silent for years. Genetic counselling, regular echocardiographic screening of first-degree relatives, and early intervention with medications or implantable devices form the cornerstone of risk mitigation in these high-risk families.

Lifestyle interventions for primary and secondary prevention strategies

While non-modifiable factors set the baseline, lifestyle interventions shape the trajectory of cardiovascular health across a lifetime. Primary prevention aims to stop heart disease before it begins, while secondary prevention focuses on preventing recurrent events in people who already have cardiovascular disease. In both scenarios, comprehensive lifestyle change—rather than addressing a single behaviour in isolation—offers the greatest protective effect.

Diet, physical activity, stress management, and sleep quality interact like pieces of a puzzle that determine overall cardiovascular risk. For example, a heart-healthy diet supports better weight control and blood pressure management, which in turn improve sleep and reduce stress levels. When we view lifestyle modification as an integrated therapeutic strategy rather than a collection of separate tasks, it becomes easier to design realistic, sustainable changes.

Mediterranean diet protocol and DASH eating plan implementation

The Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) eating plan are among the most evidence-based dietary patterns for cardiovascular risk reduction. Both emphasise high intakes of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate consumption of fish and low-fat dairy, and limited intake of red meat, processed foods, and added sugars. These dietary patterns naturally reduce saturated fat, trans fat, and sodium, while increasing fibre, antioxidants, and heart-protective unsaturated fats.

Implementing a Mediterranean-style diet in daily life can be as simple as using olive oil as the primary added fat, eating oily fish like salmon or mackerel twice a week, and basing meals around plant foods rather than meat. The DASH diet places particular emphasis on reducing sodium intake to 1,500–2,300 mg per day and increasing potassium-rich foods, which helps lower blood pressure in as little as two weeks. You might imagine your plate as a clock: at least half should be colourful vegetables and fruit, one quarter whole grains, and the remaining quarter lean protein.

Practical strategies include planning weekly menus, reading food labels to avoid high-salt and high-sugar products, and preparing home-cooked meals instead of relying on highly processed convenience foods. For individuals with established heart disease, dietitians often tailor Mediterranean or DASH principles to specific needs, such as fluid restriction in heart failure or carbohydrate control in diabetes. Over time, these dietary patterns not only reduce cardiovascular events but also support better energy levels and overall well-being.

Structured exercise prescription: high-intensity interval training vs moderate aerobic activity

Physical activity is a cornerstone of both primary and secondary cardiovascular prevention, with clear evidence that regular exercise lowers blood pressure, improves lipid profiles, reduces insulin resistance, and supports weight management. Health guidelines generally recommend at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous activity each week, along with muscle-strengthening exercises on two or more days. But how do different exercise modalities—such as high-intensity interval training (HIIT) versus steady, moderate aerobic activity—compare for heart health?

Moderate-intensity activities, such as brisk walking, cycling on level ground, or swimming at a comfortable pace, are accessible for most people and carry a low risk of injury. These forms of exercise steadily increase heart rate and breathing, improving cardiorespiratory fitness over time. HIIT involves brief bursts of vigorous exercise interspersed with recovery periods—for example, 1 minute of fast cycling followed by 2 minutes of gentle pedalling, repeated multiple times. Studies suggest that HIIT can deliver equal or greater improvements in fitness in a shorter time, which may benefit busy individuals.

However, HIIT is not suitable for everyone, especially those with poorly controlled hypertension, unstable angina, or recent cardiac events, where medical clearance and supervised cardiac rehabilitation are crucial. For many patients with heart disease, a structured programme that begins with low to moderate intensities and gradually progresses is the safest option. The key is consistency: it is better to walk 20–30 minutes most days of the week than to push yourself hard once and then stop due to fatigue or injury.

Stress management techniques: mindfulness-based stress reduction and cognitive behavioural therapy

Chronic psychological stress has been linked to elevated blood pressure, increased inflammation, and adverse health behaviours such as smoking, overeating, and physical inactivity. Over time, these effects compound the risk of heart disease. Mindfulness-based stress reduction (MBSR) and cognitive behavioural therapy (CBT) are two structured approaches that can help you manage stress and protect your cardiovascular health.

MBSR uses techniques such as mindful breathing, body scans, and gentle yoga to cultivate non-judgemental awareness of the present moment. This practice reduces activation of the sympathetic nervous system—your body’s “fight or flight” response—and can lower heart rate and blood pressure. Think of mindfulness as training the mind in the same way that exercise trains the heart: small, regular sessions build resilience over time.

CBT, on the other hand, focuses on identifying and changing unhelpful thought patterns and behaviours that contribute to stress, anxiety, or depression. In the context of cardiovascular disease, CBT can support adherence to lifestyle changes and medication, help manage fear after a heart attack, and reduce depressive symptoms that are themselves linked to poorer cardiac outcomes. Incorporating relaxation exercises, problem-solving skills, and realistic goal-setting into daily life helps break the cycle where stress leads to unhealthy habits that, in turn, increase stress.

Sleep hygiene optimisation and circadian rhythm regulation

Sleep is often overlooked in discussions about heart disease, yet poor sleep quality and short sleep duration are strongly associated with hypertension, obesity, type 2 diabetes, and coronary artery disease. Adults generally require 7–9 hours of restorative sleep per night, but modern lifestyles, screens, and irregular schedules frequently disrupt natural circadian rhythms. Obstructive sleep apnoea, characterised by repeated pauses in breathing during sleep, is particularly important, as it leads to intermittent drops in oxygen levels and significant cardiovascular strain.

Optimising sleep hygiene involves creating a consistent sleep-wake schedule, limiting caffeine and heavy meals in the evening, and keeping the bedroom dark, quiet, and cool. You can think of your pre-sleep routine as a “landing sequence” for the brain: dimming lights, reducing screen time, and engaging in relaxing activities such as reading or gentle stretching signal the body that it is time to rest. For people who snore loudly, wake up gasping, or feel unrefreshed despite adequate time in bed, assessment for sleep apnoea is essential, as treatment with CPAP (continuous positive airway pressure) significantly reduces cardiovascular risk.

Aligning daily routines with natural light-dark cycles also supports circadian rhythm regulation. Exposure to daylight in the morning and reducing bright light in the evening help regulate melatonin secretion and improve sleep onset. In individuals with existing heart disease, improved sleep is not merely a comfort issue; it can lead to better blood pressure control, improved mood, and enhanced capacity to engage in other heart-healthy behaviours.

Clinical assessment tools and diagnostic methodologies

Effective prevention and management of heart disease rely on accurate assessment of individual cardiovascular risk and early detection of structural or functional abnormalities. Clinicians use a combination of risk calculators, imaging studies, functional tests, and laboratory biomarkers to build a comprehensive picture of your heart health. These tools guide decisions about when to intensify lifestyle interventions, initiate medications, or recommend invasive procedures.

From a patient’s perspective, understanding these assessments can make consultations more meaningful and collaborative. Rather than seeing results as isolated numbers, you can view them as pieces of evidence that, together, tell the story of your cardiovascular system. How do risk scores, scans, and blood tests work together to inform your care plan? The following sections explore the most widely used methodologies.

Framingham risk score calculator and QRISK3 assessment protocol

Population-based risk calculators estimate the probability of developing cardiovascular disease over a defined period, typically 10 years. The Framingham Risk Score, derived from the long-running Framingham Heart Study, incorporates age, sex, total and HDL cholesterol, systolic blood pressure, smoking status, and presence of diabetes. It has been widely used to guide primary prevention strategies, particularly in North America, by identifying individuals who would benefit most from statins or antihypertensive therapy.

In the UK and several other regions, the QRISK3 tool is more commonly used, as it incorporates a broader range of variables relevant to contemporary, diverse populations. In addition to traditional factors, QRISK3 includes ethnicity, family history of premature heart disease, chronic kidney disease, atrial fibrillation, rheumatoid arthritis, migraine, severe mental illness, and certain medications such as corticosteroids. This allows a more nuanced estimate of risk, especially for groups historically under-represented in earlier models.

Risk scores are not diagnostic tools but decision aids. A calculated 10-year risk above a certain threshold—for example, 10% or 20%, depending on national guidelines—often triggers recommendations for more intensive lifestyle intervention and pharmacotherapy. Importantly, even if your current risk score is low, unfavourable trends over time in blood pressure, cholesterol, or weight can indicate the need for earlier action to prevent future escalation.

Coronary angiography and CT coronary angiogram interpretation

When there is a strong suspicion of coronary artery disease, imaging the coronary vessels themselves becomes necessary. Invasive coronary angiography involves threading a catheter through an artery in the wrist or groin to the coronary arteries and injecting contrast dye while X-ray images are taken. This procedure provides a detailed view of the location and severity of arterial narrowings and is often performed when revascularisation procedures such as angioplasty or stent placement may be required.

CT coronary angiography (CTCA) is a non-invasive alternative that uses computed tomography scanning with contrast to visualise the coronary arteries. CTCA is particularly useful in low- to intermediate-risk patients with chest pain, helping to rule out significant coronary stenosis and assess overall plaque burden. It can also detect non-obstructive plaques that might not yet be causing symptoms but still confer risk, guiding earlier preventive interventions.

Interpretation of both invasive angiography and CTCA focuses on the degree of luminal narrowing, plaque characteristics (such as calcified versus soft plaques), and overall distribution of disease. A finding of multi-vessel or left main coronary artery disease generally indicates a higher risk and may prompt referral for coronary artery bypass grafting (CABG). Conversely, normal or near-normal imaging can provide reassurance and refocus attention on lifestyle measures and medical therapy to prevent disease progression.

Echocardiography parameters: left ventricular ejection fraction and diastolic function

Echocardiography uses ultrasound waves to create real-time images of the heart’s structure and function. It is a cornerstone investigation in cardiology because it is non-invasive, widely available, and free of radiation. Two key parameters—left ventricular ejection fraction (LVEF) and diastolic function—provide crucial information about how well the heart is pumping and relaxing.

LVEF represents the percentage of blood ejected from the left ventricle with each heartbeat, with normal values typically ranging from 50% to 70%. Reduced LVEF indicates systolic dysfunction and is a hallmark of heart failure with reduced ejection fraction (HFrEF), often due to previous myocardial infarction, long-standing hypertension, or cardiomyopathy. The degree of reduction in LVEF helps stratify risk and determine the intensity of pharmacological and device-based therapies.

Diastolic function assessment evaluates how effectively the left ventricle relaxes and fills with blood between beats. Diastolic dysfunction can occur even when LVEF is preserved and is a key feature of heart failure with preserved ejection fraction (HFpEF), a condition increasingly recognised in older adults, particularly women with hypertension and diabetes. Echocardiographic measurements such as transmitral flow patterns, tissue Doppler velocities, and left atrial size collectively inform diastolic grading and guide management strategies.

Biomarker analysis: troponin levels, BNP, and c-reactive protein significance

Biochemical markers measured in blood provide dynamic information about myocardial injury, wall stress, and systemic inflammation. Cardiac troponins I and T are highly specific markers of heart muscle damage and are central to the diagnosis of acute myocardial infarction. Elevated troponin levels, in combination with characteristic symptoms and ECG changes, confirm the presence of a heart attack and guide urgent reperfusion therapy.

B-type natriuretic peptide (BNP) and its inactive fragment NT-proBNP are released from ventricular myocytes in response to increased wall stress and volume overload. Elevated BNP levels support the diagnosis of heart failure, help differentiate cardiac from non-cardiac causes of breathlessness, and provide prognostic information. Serial measurements can also be used to monitor response to therapy, with declining levels indicating improved haemodynamic status.

C-reactive protein (CRP), particularly high-sensitivity CRP (hs-CRP), is a non-specific marker of systemic inflammation that has been associated with increased cardiovascular risk, even after adjusting for traditional risk factors. While CRP is not used in isolation to make treatment decisions, elevated levels may reflect underlying inflammatory atherosclerosis and support more aggressive risk-factor modification. Together, these biomarkers complement imaging and clinical assessment, adding another layer to personalised cardiovascular risk stratification.

Pharmacological interventions and Evidence-Based treatment protocols

When lifestyle modification alone is insufficient to control cardiovascular risk, pharmacological therapy becomes essential. Modern treatment protocols are grounded in large randomised controlled trials demonstrating that specific drug classes reduce heart attacks, strokes, and cardiovascular mortality. The choice and intensity of therapy depend on overall risk, co-existing conditions, and tolerance to medications.

Statins remain the first-line agents for lowering LDL cholesterol and stabilising atherosclerotic plaques, with high-intensity statins recommended for individuals with established cardiovascular disease or very high risk. Ezetimibe and PCSK9 inhibitors may be added when LDL targets are not achieved. Antihypertensive regimens typically include ACE inhibitors or angiotensin receptor blockers, calcium channel blockers, and thiazide-like diuretics, often in combination, to achieve blood pressure targets below 130/80 mmHg in many high-risk patients.

Antiplatelet therapy, such as low-dose aspirin or P2Y₁₂ inhibitors, plays a central role in secondary prevention after myocardial infarction or stent placement by reducing the risk of thrombotic events. In selected high-risk primary prevention patients, low-dose aspirin may also be considered, balancing cardiovascular benefit against bleeding risk. For those with heart failure, evidence-based regimens now include ACE inhibitors or ARNI (angiotensin receptor–neprilysin inhibitors), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, which together significantly improve survival and quality of life.

Advanced prevention strategies: precision medicine and emerging technologies

As our understanding of cardiovascular disease evolves, prevention strategies are moving beyond a one-size-fits-all model toward precision medicine. Genetic profiling, polygenic risk scores, and advanced imaging of plaque characteristics allow more refined risk prediction in certain populations. For example, coronary artery calcium (CAC) scoring by CT quantifies calcified plaque and can reclassify individuals from intermediate to higher or lower risk, thereby guiding decisions on statin therapy.

Emerging technologies also include wearable devices that continuously monitor heart rate, rhythm, physical activity, and even blood pressure, providing real-time data that can prompt timely interventions. Mobile health applications support medication adherence, lifestyle tracking, and remote coaching, making heart disease prevention more proactive and personalised. For people with known arrhythmias or implanted devices, remote monitoring systems alert clinicians to clinically significant changes before symptoms arise.

In the research arena, therapies targeting inflammation within atherosclerotic plaques, novel lipid-lowering agents, and gene-editing approaches for monogenic disorders such as familial hypercholesterolaemia hold promise for the future. While many of these interventions are still in early stages or limited to specialised centres, they signal a shift towards more tailored, mechanism-based prevention strategies that go beyond traditional risk-factor control.

Monitoring and Long-Term management: secondary prevention after cardiac events

For individuals who have experienced a heart attack, stroke, or undergone procedures such as coronary angioplasty or bypass surgery, secondary prevention is critical to reduce the likelihood of recurrent events. This involves a structured combination of lifestyle modification, optimal pharmacotherapy, and regular follow-up. Cardiac rehabilitation programmes, which integrate supervised exercise, education, and psychological support, have been shown to reduce mortality and hospital readmissions while improving quality of life.

Ongoing monitoring typically includes periodic assessment of blood pressure, lipid profiles, HbA1c in those with diabetes, kidney function, and adherence to medications. Adjustments are made as needed to maintain targets, manage side effects, and respond to changes in clinical status. You can think of secondary prevention as long-term maintenance of a complex system: small, regular checks and adjustments prevent major breakdowns.

Equally important is addressing psychosocial factors such as depression, anxiety, and fear of exertion, which are common after cardiac events and can undermine adherence to treatment plans. Encouraging open communication with healthcare providers, involving family members in education, and accessing community or online support groups can help sustain motivation. With consistent engagement in secondary prevention strategies, many people not only avoid further cardiac events but also regain a high level of functional capacity and confidence in their day-to-day lives.